Metabolic biomarkers related to cardiac dysfunction in metabolic-dysfunction-associated fatty liver disease: a cross-sectional analysis.
Journal
Nutrition & diabetes
ISSN: 2044-4052
Titre abrégé: Nutr Diabetes
Pays: England
ID NLM: 101566341
Informations de publication
Date de publication:
18 01 2022
18 01 2022
Historique:
received:
15
08
2021
accepted:
07
12
2021
revised:
17
11
2021
entrez:
19
1
2022
pubmed:
20
1
2022
medline:
31
3
2022
Statut:
epublish
Résumé
Hepatic steatosis is associated with cardiac systolic and diastolic dysfunction. Therefore, we evaluated metabolites and their potential cardiovascular effects in metabolic-dysfunction-associated fatty liver disease (MAFLD). We conducted a cross-sectional study involving 75 participants (38 MAFLD and 37 controls). Hepatic steatosis was confirmed by hepatic ultrasonography and SteatoTest The median age for participants' age was 45 (IQR 30-56.5), with gender distribution of 35 males and 40 females. MAFLD patients had lower levels of glycyl tyrosine (p-value < 0.001), lysophosphatidylcholine (LPC) (18:2/0:0) (p-value < 0.001), LPC (22:6) (p-value < 0.001), and ceramide (Cer) (d18:0/23:0) (p-value 0.003) compared to controls. MAFLD patients presented lower left ventricular ejection fraction (LVEF), E/A ratio, E/e' ratio, and average global longitudinal strain (GLS) values, with a p-value of 0.047, <0.001, 0.008, and <0.001, respectively. Decreased glycyl tyrosine levels were significantly correlated with reduced LVEF, even after performing multiple linear regression with 95% CI (1.34-3.394, p-value < 0.001). Moreover, decreased LPC (18:2/0:0) levels remained significantly associated with E/A ratio, even after adjusting for confounding factors with 95% CI (0.008-0.258, p-value = 0.042). MAFLD patients are at risk for developing cardiac systolic and subclinical systolic dysfunctions, as well as diastolic dysfunction. Decreased glycyl tyrosine levels correlate with reduced LVEF and LPC (18:2/0:0) levels with diastolic dysfunction, even after adjusting for confounding factors, suggesting their potential to be used as metabolic biomarkers in detecting cardiovascular risk.
Identifiants
pubmed: 35042855
doi: 10.1038/s41387-022-00182-7
pii: 10.1038/s41387-022-00182-7
pmc: PMC8764324
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4Informations de copyright
© 2022. The Author(s).
Références
Heart. 2006 Aug;92(8):1102-8
pubmed: 16387826
Indian Heart J. 2013 Jan-Feb;65(1):117-23
pubmed: 23438628
Gastroenterology. 2020 May;158(7):1999-2014.e1
pubmed: 32044314
Med Ultrason. 2014 Sep;16(3):236-45
pubmed: 25110765
J Am Soc Echocardiogr. 2014 Aug;27(8):858-871.e1
pubmed: 24975996
Liver Int. 2020 Sep;40(9):2082-2089
pubmed: 32478487
World J Hepatol. 2015 Jun 18;7(11):1586-94
pubmed: 26085918
Obes Facts. 2017;10(5):483-492
pubmed: 29020674
Diabetologia. 2020 Feb;63(2):253-260
pubmed: 31713012
Sci Rep. 2017 Jul 26;7(1):6619
pubmed: 28747790
Cell Rep Med. 2020 Dec 22;1(9):100154
pubmed: 33377125
J Manag Care Pharm. 2003 Jan-Feb;9(1 Suppl):2-5
pubmed: 14613351
Comp Hepatol. 2005 Dec 23;4:10
pubmed: 16375767
J Am Soc Echocardiogr. 2016 Apr;29(4):277-314
pubmed: 27037982
J Gastroenterol Hepatol. 2018 Jan;33(1):86-98
pubmed: 28692197
Panminerva Med. 2021 Dec;63(4):508-518
pubmed: 33165307
Expert Rev Mol Diagn. 2007 Sep;7(5):481-90
pubmed: 17892356
Hepatology. 2016 Jul;64(1):73-84
pubmed: 26707365
Nutr Metab (Lond). 2017 Sep 2;14:58
pubmed: 28878811
Int J Obes (Lond). 2015 Mar;39(3):397-407
pubmed: 25199621
Diabetes Care. 2021 Jan;44(Suppl 1):S15-S33
pubmed: 33298413
Eur Heart J. 2018 Feb 1;39(5):385-393
pubmed: 29228164
Eur J Echocardiogr. 2006 Mar;7(2):79-108
pubmed: 16458610
Can J Gastroenterol Hepatol. 2020 Nov 30;2020:8825615
pubmed: 33313020
Lancet Gastroenterol Hepatol. 2021 Sep;6(9):743-753
pubmed: 34265276
Sci Rep. 2018 Sep 21;8(1):14200
pubmed: 30242179
J Hepatol. 2020 Jul;73(1):202-209
pubmed: 32278004
Hypertension. 2020 Jun;75(6):1334-1357
pubmed: 32370572
Gastroenterol Clin North Am. 2016 Dec;45(4):639-652
pubmed: 27837778
Biomed Res Int. 2015;2015:213737
pubmed: 26273598
Metabolites. 2018 Feb 24;8(1):
pubmed: 29495258
Sci Rep. 2019 Jul 31;9(1):11124
pubmed: 31366982
Diabetologia. 2017 Jul;60(7):1218-1222
pubmed: 28352941
Clin Liver Dis. 2018 Feb;22(1):141-174
pubmed: 29128054
J Clin Med. 2021 Jul 07;10(14):
pubmed: 34300193
Nutr Metab (Lond). 2018 Jul 17;15:51
pubmed: 30026784
Eur J Clin Invest. 2020 Oct;50(10):e13331
pubmed: 32589269
Metabolism. 2011 Mar;60(3):313-26
pubmed: 21040935
Liver Int. 2019 Mar;39(3):557-567
pubmed: 30358050
Dig Liver Dis. 2018 Nov;50(11):1166-1175
pubmed: 30292566
Eur Heart J Cardiovasc Imaging. 2013 Jul;14(7):611-44
pubmed: 23733442
Cytokine. 2020 Feb;126:154927
pubmed: 31756645
Eur J Gastroenterol Hepatol. 2003 May;15(5):539-43
pubmed: 12702913
J Am Soc Echocardiogr. 2004 Jun;17(6):630-3
pubmed: 15163933